infection and are expressed as IU/ml based on human IFN-a standard G-023-091-527 (National Institutes of Health, Bethesda, MD) . Samples were tested for acid lability by dialysis in 100 mM glycine-HCI (pH 2) for 24 h at 4°C, followed by dialysis in PBS (pH 7.4) for another 24 h at 4°C (3) . Control preparations were dialyzed in PBS throughout the 48 h.
Standard Interferons and Neutralizing Antibodies. NK-2 IFN-a is a natural preparation of different IFN-a produced by human lymphoblastoid cells (Celltech Limited, Berkshire, UK). Purified human rIFN-a2 and rIFN-Q,er1, were from Schering Corp. (Bloomfield, NJ) and Cetus Corp. (Emeryville, CA), respectively. Human IFN-y was prepared according to the method ofYip et al. (11) . Polyclonal sheep anti-IFN-a antibodies were obtained from Interferon Sciences, Inc. (New Brunswick, NJ) . Polyclonal bovine anti-IFN-(3 antibodies were provided by Dr. Jan ViRek (NYU School of Medicine, New York, NY) . Polyclonal rabbit anti-IFN-y antibodies were prepared by published methods (12) . Antibody neutralization assays, described elsewhere (3), were conducted using preimmune sheep, bovine, or rabbit sera as negative controls. rIFN-a2 was radioiodinated with 1z'I using the Bolton-Hunter reagent (reference 13; New England Nuclear, Boston, MA) .
Fast Protein Liquid Chromatography (FPLC).' All chromatographic methods were performed using the FPLC System (Pharmacia Fine Chemicals, Piscataway, NJ) . Anion exchange chromatography was done by loading samples onto the Mono Q HR 10/10 column equilibrated in 20 mM Tris (pH 7.5) and eluting with a linear gradient of NaCl from 0 to 700 mM at a flow rate of 4.00 ml/min . Chromatofocusing on the Mono P HR 5/20 column and gel filtration on the Superose 12 HR 10/30 column are described in the figure legends . Elution profiles were monitored by UV absorbance at 280 nm.
Miscellaneous Protein Manipulations . Protein preparations were concentrated in dialysis tubing using Aquacide II (Calbiochem-Behring Corp., LaJolla, CA) .
Results
Physicochemical Characterization ofSLE IFN-a . 360 serum and plasma samples from 104 SLE patients were screened for the presence of IFN activity, and in agreement with earlier reports (2, 3), 44 individuals (42%) exhibited significant IFN activity (>8 IU/ml) on at least one occasion, while no normal serum or plasma (n = 7) exhibited any IFN activity. The IFN activity from two SLE patients, DS and DT, was found to conform to the previously reported acid-labile IFN-a. The IFNs from both patients are reduced to <20% of original activity by anti-IFN-a antibodies, but are unaffected by antibodies against IFN-(3 and IFN-y (Table I ). This incomplete neutralization has been observed by others (3, 4) . Simultaneous incubation of the SLE IFN with all three panels of antibodies abrogates the IFN activity to the same degree as with anti-IFN-a antibodies alone (data not shown), thus ruling out the presence of trace amounts of IFN-0 or IFN-y in the plasma. In addition, the results in Table  II show that IFN activity from DS and DT is acid labile ; standard IFN-a and IFN-(3 remain active after acid dialysis, while IFN-y, known to be acid labile, is inactivated .
The charge properties of SLE IFN-a from DS and DT were compared with those of reference NK-2 IFN-ca by FPLC/Mono Qanion-exchange chromatography. Both were found to bind avidly to the anion exchange column at pH 7 .5, requiring 250 to 300 mM NaCl to elute from the column (data not shown) . The similarity in charge properties between SLE and standard IFN-a was further confirmed by chromatofocusing experiments (Fig. 1) . SLE IFN was eluted from the Mono P column by Polybufl'er around pH 5.1 (panel A), while the bulk of NK-2 IFN-a was eluted within a pH range of 4.8 to 5.5 (panel B). All known subspecies of IFN-a have isoelectric points between 5 .0 and 7 .0 (11).
Representative results from multiple experiments (n = 3) . ' Parentheses denote percent activity relative to control incubation with preimmune sera . 1 IFN-positive fractions were pooled after fractionation and concentrated before assay .
FPLC/Mono Qchromatography results in a 90-95% recovery and an approximately sixfold purification of SLE IFN activity (data not shown) . Gel filtration of Mono Q-enriched SLE IFN on the Superose 12 column revealed a single peak of IFN activity, eluting in fractions corresponding to -19 kD, which is within the molecular mass range of known IFN-a subspecies (14) and coincident with the elution of "'I-rIFN-ot2 (Fig. 2) . Unpurified plasma SLE IFN-a also elutes in fractions corresponding to 19 kD (data not shown) . This result and the high recovery yield confirm that Mono Q-purified SLE IFN is representative of that in unfractionated plasma . Further, antibody neutralization assays verify that Mono Q-purified IFN from DS and DT is specifically inhibited by antibodies against IFN-CI (Table I) .
SLE IFN-a is Acid Stable. More significantly, however, when Mono Q-purified SLE IFN-a from DS and DT was dialyzed in acid, the IFN activity was completely TABLE 11 Acid Stability of Interferons Representative results from multiple experiments (n -5) . ' Samples were diluted in normal human plasma . T Parentheses denote percent activity relative to control dialysis in PBS . S IFN-positive fractions were pooled after fractionation and concentrated before assay . unaffected (Table II) , suggesting that the apparent acid lability of SLE IFN-a is caused by other factor(s) in SLE plasma that are removed during partial purification .
Acid-dependent IFN-inactivating Factor(s) in SLE Plasma. To test this hypothesis, the effects of SLE plasma on acid-stable NK-2 IFN-a were examined . NK-2 IFN-a was diluted 1 :10 (vol/vol) in plasma from either normal or SLE individuals to a final concentration of 512 1U/ml of exogenous IFN activity and was then tested for acid lability. Acid dialysis of NK-2 IFN-a diluted in plasma from DS and DT largely Elution Volume (ml) 0 5 FIGURE 2. FPLC/Superose 12 gel filtration of Mono Q-purified SLE IFN from DS plasma . Mono Q-purified IFN activity from DS was concentrated, dialyzed in PBS, and then fractionated into 0.40-ml fractions at a flow rate of 0.50 ml/ min. Antiviral activity of fractions is illustrated by solid lines (-); absorbance of eluate at 280 nm (A28onm) is indicated by the evenly broken line (---) ; molecular weight calibration is denoted by the unevenly broken line (------) . The Superose 12 column was calibrated using the following molecularmass standards: IgG (150 kD), BSA (66.2 kD), OVA (42.7 kD), cytochrome c (12.2 kD), and vitamin B12 (1,355 daltons) . In parallel experiments, 60 x 10 3 cpm of 125 1-rIFNa2 were similarly fractionated ; radioactivity of individual fractions was quantitated with a gamma counter ( . -0 --) . inactivated the bulk of both exogenous and endogenous IFN activities (Table III) . Additional experiments reveal that 8 of 13 samples from other SLE patients also exhibit similar acid-dependent IFN-inactivating activity and that the presence of such activity is independent of the levels of endogenous IFN (data not shown) . No normal plasma showed this property (Table III) .
To further test the idea that the acid lability of SLE IFN-a is due to the effects of factors not intrinsic to the IFN, the IFN-negative fractions recovered during Mono Q anion-exchange chromatography of plasma from DS were assayed for aciddependent IFN-inactivating activity. Fractions from the column flow-through and from the salt eluate which lacked IFN activity were pooled separately and concentrated to original sample volume . The column flow-through, but not the salt eluate, inactivated NK-2 IFN-a after acid dialysis (Table III) , suggesting that factor(s) not adsorbing to the Mono Qcolumn at pH 7.5 may account for the apparent acid lability of SLE IFN-a .
Discussion
Four lines ofevidence have been advanced in this report to suggest that SLE IFN-a is physicochemically very similar to known IFN-a and that its acid lability is not an intrinsic property of the SLE IFN-a, but rather the result ofother factor(s) present in SLE plasma . First, with respect to antigenicity, size, and isoelectric point, SLE IFN-a is indistinguishable from conventional IFN-a. Second, when SLE IFN-a is partially purified by anion-exchange chromatography, it no longer exhibits acid lability. Third, when exogenous acid-stable IFN-a is diluted in SLE plasma or serum, it as well as the endogenous IFN is inactivated after acid dialysis . And last, an aciddependent IFN-inactivating activity can be partially purified from SLE plasma by anion-exchange chromatography.
These observations have important implications for the study of the IFN system in SLE. Much effort has been expended to clone the large family of human IFN-a genes and pseudogenes, none of which encode proteins that are acid labile (14) . Since it is now shown that SLE IFN-a is not intrinsically acid labile, it is quite possible that one or more of the already described IFN-a may represent the IFN-a subspecies observed in SLE. Thus, the necessary reagents for the study of the IFN system in SLE may already be available for use. Indeed, various subspecies of IFN-a have been shown to stimulate polyclonal B cell activation (15) , to inhibit Ts cell function (16) , and to modulate expression of HLA class I antigens (17) , all of which have been implicated in the induction of autoimmunity. Alternatively, IFN-a may be involved in the efferent limb of pathology in SLE. Experimental and therapeutic administration of IFN-a have been shown to cause clinical signs and symptoms of SLElike illness in animals and in humans (18) . The significance of acid-dependent IFN-inactivating factor(s) and whether this activity is an integral component of the IFN system in SLE remain to be elucidated . It has been reported that the acid stability of serum IFN-a in AIDS and AIDSrelated complex (ARC) decreases with progression of disease, perhaps secondary to the increasing concentration of serum factors such as immunoglobulins, immune complexes, and autoantibodies during the course of illness (8) . This speculation may have relevance in SLE, since anti-IFN-a antibodies have been described in some SLE patients (19) . However, the nature of acid lability of IFN-a in AIDS/ARC also has not been established, and it would be of interest to determine if findings with acid-labile IFN-a in AIDS/ARC will be similar to those presented here for SLE . Although a change in the acid stability of serum IFN-a in SLE over time has been reported (4), no data on any relationship between acid stability and clinical disease are available. In view of the increasingly recognized similarities between AIDSJARC and SLE (7), such a study may shed light on possible common pathogenetic or pathological pathways in these disorders. Work to identify the acid-dependent IFNinactivating factor(s) is currently in progress .
Summary
The physicochemical properties of apparently acid-labile IFN-a from patients with SLE have been studied . The antigenicity, apparent molecular size, and isoelectric point of SLE IFN-ac are indistinguishable from those of conventional, previously characterized, acid-stable subspecies of IFN-a. However, after partial purification by anion-exchange chromatography, SLE IFN-a no longer exhibits acid lability, suggesting that other plasma factor(s) are responsible for the acid lability of SLE IFN-a . Addition of SLE plasma, but not normal plasma, to conventional acid-stable IFN-a renders the exogenous IFN-a acid labile . Preliminary results demonstrate that an acid-dependent IFN-inactivating activity can be partially purified from SLE plasma by anion-exchange chromatography.
